Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNMNASDAQ:BLUENASDAQ:IPSCNASDAQ:NEUP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.69+0.6%$1.45$1.03▼$8.64$52.72M-0.27498,244 shs42,294 shsBLUEbluebird bio$4.97$4.51$3.20▼$28.60$48.67M0.27432,306 shsN/AIPSCCentury Therapeutics$0.57-0.5%$0.51$0.34▼$3.46$48.87M1.8585,603 shs220,050 shsNEUPNeuphoria Therapeutics Inc. - Common Stock$7.20+5.1%$5.39$2.12▼$12.55$13.54M0.26335,013 shs24,164 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals+3.70%+1.82%+8.39%+46.09%-79.39%BLUEbluebird bio+0.20%-0.60%+25.82%+24.25%-74.21%IPSCCentury Therapeutics+4.89%+1.51%+3.65%-6.17%-80.87%NEUPNeuphoria Therapeutics Inc. - Common Stock-2.28%+1.63%+35.64%+31.98%+684,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNMActinium Pharmaceuticals1.5621 of 5 stars3.42.00.00.01.70.00.6BLUEbluebird bio3.1428 of 5 stars3.15.00.00.02.31.71.3IPSCCentury Therapeutics2.5172 of 5 stars3.53.00.00.02.21.70.6NEUPNeuphoria Therapeutics Inc. - Common Stock1.6423 of 5 stars3.50.00.00.02.20.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 2.75Moderate Buy$4.00136.69% UpsideBLUEbluebird bio 2.25Hold$44.60797.38% UpsideIPSCCentury Therapeutics 3.00Buy$4.20640.48% UpsideNEUPNeuphoria Therapeutics Inc. - Common Stock 3.00Buy$21.00191.67% UpsideCurrent Analyst Ratings BreakdownLatest NEUP, BLUE, ATNM, and IPSC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025IPSCCentury TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $6.005/12/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/28/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/3/2025IPSCCentury TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $2.004/1/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/31/2025BLUEbluebird bioBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $8.003/28/2025IPSCCentury TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/25/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/24/2025IPSCCentury TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $7.003/21/2025IPSCCentury TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $5.003/20/2025IPSCCentury TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.00 ➝ $2.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium Pharmaceuticals$81K650.88N/AN/A$1.31 per share1.29BLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14IPSCCentury Therapeutics$114.90M0.43N/AN/A$3.06 per share0.19NEUPNeuphoria Therapeutics Inc. - Common Stock$15.66M0.86N/AN/A$7.82 per share0.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$1.39N/AN/AN/AN/A-100.85%-47.89%N/ABLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%8/14/2025 (Estimated)IPSCCentury Therapeutics-$136.67M-$0.29N/AN/AN/A-4,837.73%-61.66%-31.78%8/14/2025 (Estimated)NEUPNeuphoria Therapeutics Inc. - Common Stock-$15.49MN/A0.00N/AN/AN/AN/AN/AN/ALatest NEUP, BLUE, ATNM, and IPSC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q3 2025NEUPNeuphoria Therapeutics Inc. - Common Stock-$0.47$6.55+$7.02$6.55N/A$15.00 million5/15/2025Q1 2025IPSCCentury Therapeutics-$0.31$0.89+$1.20$0.89$45.52 million$109.16 million3/19/2025Q4 2024IPSCCentury Therapeutics-$0.45-$0.43+$0.02-$0.43$0.67 million$4.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/ANEUPNeuphoria Therapeutics Inc. - Common StockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25BLUEbluebird bio0.370.510.33IPSCCentury TherapeuticsN/A10.3910.39NEUPNeuphoria Therapeutics Inc. - Common StockN/A2.063.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%BLUEbluebird bio87.43%IPSCCentury Therapeutics50.20%NEUPNeuphoria Therapeutics Inc. - Common Stock15.90%Insider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals6.00%BLUEbluebird bio1.40%IPSCCentury Therapeutics6.80%NEUPNeuphoria Therapeutics Inc. - Common Stock0.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableIPSCCentury Therapeutics17086.16 million79.25 millionOptionableNEUPNeuphoria Therapeutics Inc. - Common StockN/A1.88 million1.75 millionN/ANEUP, BLUE, ATNM, and IPSC HeadlinesRecent News About These CompaniesNeuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual MeetingMay 27, 2025 | globenewswire.comNeuphoria Therapeutics, Inc.: Neuphoria Provides First Quarter 2025 Business UpdatesMay 21, 2025 | finanznachrichten.deNeuphoria Provides First Quarter 2025 Business UpdatesMay 20, 2025 | globenewswire.comNeumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comNeuphoria Therapeutics provides review of 2024, highlights 2025 plansApril 16, 2025 | markets.businessinsider.comNeuphoria Provides a Review of 2024 and Highlights 2025 PlansApril 15, 2025 | globenewswire.comNeuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025March 3, 2025 | globenewswire.comNeuphoria Therapeutics Inc. to Receive $15M Milestone Payment from MerckFebruary 12, 2025 | globenewswire.comHere's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep goingFebruary 6, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s Watching3 Alternative Asset Managers Are Raising Dividends by 5% to 25%By Leo Miller | May 13, 2025View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%Don’t Take Dick’s Sporting Goods Seriously? Big MistakeBy Thomas Hughes | May 29, 2025View Don’t Take Dick’s Sporting Goods Seriously? Big MistakeNEUP, BLUE, ATNM, and IPSC Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$1.69 +0.01 (+0.60%) As of 01:16 PM EasternActinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.bluebird bio NASDAQ:BLUE$4.97 0.00 (0.00%) As of 06/2/2025bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Century Therapeutics NASDAQ:IPSC$0.57 0.00 (-0.51%) As of 01:22 PM EasternCentury Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Neuphoria Therapeutics Inc. - Common Stock NASDAQ:NEUP$7.20 +0.35 (+5.11%) As of 01:21 PM EasternNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
